NASDAQ:ENDP - Endo International Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.10 -0.10 (-1.61 %)
(As of 05/20/2018 04:00 PM ET)
Previous Close$6.10
Today's Range$6.0130 - $6.21
52-Week Range$5.27 - $14.15
Volume4.01 million shs
Average Volume4.82 million shs
Market Capitalization$1.37 billion
P/E Ratio1.59
Dividend YieldN/A
Beta0.34

About Endo International (NASDAQ:ENDP)

Endo International logoEndo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The U.S. Branded Pharmaceuticals segment provides XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's diseases; SUPPRELIN LA for central precocious puberty treatment; TESTOPEL, a long-acting implantable pellet for the treatment of central precocious puberty; NASCOBAL, a nasal spray to treat vitamin B12 deficiency; and AVEED for the treatment of hypogonadism. This segment also offers pain management products, such as PERCOCET, VOLTAREN Gel, and LIDODERM; TESTIM Gel for the treatment of endogenous testosterone; and FORTESTA Gel for hypogonadism treatment. The International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Receive ENDP News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ENDP
CUSIP29264F20
Phone011-353-1268-2000

Debt

Debt-to-Equity Ratio-1,161.84
Current Ratio1.06
Quick Ratio0.88

Price-To-Earnings

Trailing P/E Ratio1.59
Forward P/E Ratio2.58
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.47 billion
Price / Sales0.39
Cash Flow$8.3562 per share
Price / Cash0.73
Book Value($0.03) per share
Price / Book-203.33

Profitability

EPS (Most Recent Fiscal Year)$3.84
Net Income$-2,035,430,000.00
Net Margins-75.58%
Return on Equity143.46%
Return on Assets6.30%

Miscellaneous

Employees3,039
Outstanding Shares223,790,000

Endo International (NASDAQ:ENDP) Frequently Asked Questions

What is Endo International's stock symbol?

Endo International trades on the NASDAQ under the ticker symbol "ENDP."

How were Endo International's earnings last quarter?

Endo International plc (NASDAQ:ENDP) posted its quarterly earnings results on Tuesday, May, 8th. The company reported $0.67 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.55 by $0.12. The company had revenue of $700.53 million for the quarter, compared to the consensus estimate of $691.94 million. Endo International had a negative net margin of 75.58% and a positive return on equity of 143.46%. Endo International's revenue was down 32.5% on a year-over-year basis. During the same quarter last year, the firm posted $1.23 earnings per share. View Endo International's Earnings History.

When is Endo International's next earnings date?

Endo International is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Endo International.

What guidance has Endo International issued on next quarter's earnings?

Endo International updated its FY18 earnings guidance on Tuesday, May, 8th. The company provided EPS guidance of $2.15-2.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.34. The company issued revenue guidance of $2.6-2.8 billion, compared to the consensus revenue estimate of $2.74 billion.

What price target have analysts set for ENDP?

20 Wall Street analysts have issued twelve-month price objectives for Endo International's shares. Their predictions range from $7.00 to $16.00. On average, they anticipate Endo International's share price to reach $9.4063 in the next twelve months. View Analyst Ratings for Endo International.

What are Wall Street analysts saying about Endo International stock?

Here are some recent quotes from research analysts about Endo International stock:
  • 1. According to Zacks Investment Research, "Endo’s guidance for 2018 was way below expectations. The generics business is under tremendous pressure due to the loss of marketing exclusivity for the first-to-file products ezetimibe tablets and quetiapine ER tablets in the first half of 2017. The branded pharmaceuticals business was impacted by continued generic competition for established products, product divestitures and ceasing shipments of Opana ER and this is expected to continue further. Endo withdrew opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA’s request in June 2017.  The company divested its non-core assets such as Belbuca and restructured its pain franchise to focus particularly on specialty branded business. However, we expect challenging business conditions for the company in 2018. Shares have underperformed the industry over a year." (5/1/2018)
  • 2. Cantor Fitzgerald analysts commented, "Takeaways from the quarter: 1) Executing well against its stated objectives in U.S. generics, during 4Q17, the U.S. generics segment launched six products and submitted two regulatory filings. In 2017, the U.S. generics segment launched 17 products and ENDP made 12 regulatory submissions. As of 12/31/17, ENDP had ~100 ANDAs (~1/3 FTF/FTM) pending with the FDA. 2) Sterile Injectables is a growing franchise. Sterile Injectables revenue increased 16% YOY. This increase was driven by Adrenalin. 3) Important sterile injectable drugs include Vasostrict and Adrenalin. ENDP reported 2017 Vasostrict sales of $400MM and Adrenalin sales of $77MM. 4) As of 12/31/17, ENDP had $987MM in unrestricted cash, net debt of ~$7.3B and a net leverage ratio of 4.6x. 5) 4Q17 cash provided by operating activities was $132MM, compared to $84MM of net cash provided by operating activities in 2016. 6) Cellulite could be a big opportunity for ENDP. RELEASE-1 And RELEASE-2 Phase 3 trials looking at Xiaflex for the treatment cellulite were initiated. Topline data are expected 1Q19. ENDP plans to submit all the data in 2019. ENDP expects to commercialize the product on its own, but would consider strategic alternatives. 7) ENDP thinks that the generic market seems more stable, but it is still early in 2018." (2/27/2018)
  • 3. Mizuho analysts commented, "We Lower PT to $12 from $14; Buy on Valuation Rating Buy Previous Rating No Change Price (1/02) $8.10 Price Target $12.00 Previous Price Target $14.00 Summary We reiterate our Buy rating but lower our PT to $12 from $14. We think 2018 guidance may prove disappointing, but we continue to view the stock as undervalued." (1/3/2018)

Are investors shorting Endo International?

Endo International saw a decline in short interest in the month of April. As of April 30th, there was short interest totalling 32,207,296 shares, a decline of 4.7% from the April 13th total of 33,791,139 shares. Based on an average trading volume of 4,032,480 shares, the days-to-cover ratio is presently 8.0 days. Approximately 16.1% of the shares of the stock are short sold.

Who are some of Endo International's key competitors?

Who are Endo International's key executives?

Endo International's management team includes the folowing people:
  • Mr. Paul V. Campanelli, Pres, CEO & Director (Age 56)
  • Mr. Blaise Coleman, Exec. VP & CFO (Age 44)
  • Mr. Terrance J. Coughlin, Exec. VP & COO (Age 52)
  • Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 46)
  • Ms. Carrie A. Nichol CPA, VP, Controller & Chief Accounting Officer (Age 38)

Has Endo International been receiving favorable news coverage?

Press coverage about ENDP stock has been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Endo International earned a news impact score of 0.15 on Accern's scale. They also gave press coverage about the company an impact score of 48.71 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Endo International's major shareholders?

Endo International's stock is owned by a number of of institutional and retail investors. Top institutional investors include BNP Paribas Arbitrage SA (1.47%), Diamond Hill Capital Management Inc. (0.49%), New York State Common Retirement Fund (0.25%), Alps Advisors Inc. (0.20%), Schroder Investment Management Group (0.19%) and American International Group Inc. (0.18%). Company insiders that own Endo International stock include Blaise Coleman, Matthew Joseph Maletta, Nancy J Hutson, Paul Campanelli, Roger H Kimmel and Terrance J Coughlin. View Institutional Ownership Trends for Endo International.

Which major investors are selling Endo International stock?

ENDP stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., New York State Common Retirement Fund, Van ECK Associates Corp, New York State Teachers Retirement System, American International Group Inc., California State Teachers Retirement System, Rhumbline Advisers and Gamco Investors INC. ET AL. View Insider Buying and Selling for Endo International.

Which major investors are buying Endo International stock?

ENDP stock was bought by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Schroder Investment Management Group, Alps Advisors Inc., Diamond Hill Capital Management Inc., Systematic Financial Management LP, Flinton Capital Management LLC, Tyers Asset Management LLC and Riverhead Capital Management LLC. Company insiders that have bought Endo International stock in the last two years include Blaise Coleman, Matthew Joseph Maletta, Paul Campanelli and Terrance J Coughlin. View Insider Buying and Selling for Endo International.

How do I buy shares of Endo International?

Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endo International's stock price today?

One share of ENDP stock can currently be purchased for approximately $6.10.

How big of a company is Endo International?

Endo International has a market capitalization of $1.37 billion and generates $3.47 billion in revenue each year. The company earns $-2,035,430,000.00 in net income (profit) each year or $3.84 on an earnings per share basis. Endo International employs 3,039 workers across the globe.

How can I contact Endo International?

Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]


MarketBeat Community Rating for Endo International (ENDP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  675 (Vote Outperform)
Underperform Votes:  625 (Vote Underperform)
Total Votes:  1,300
MarketBeat's community ratings are surveys of what our community members think about Endo International and other stocks. Vote "Outperform" if you believe ENDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENDP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Endo International (NASDAQ:ENDP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
20 Wall Street analysts have issued ratings and price targets for Endo International in the last 12 months. Their average twelve-month price target is $9.4063, suggesting that the stock has a possible upside of 54.20%. The high price target for ENDP is $16.00 and the low price target for ENDP is $7.00. There are currently 1 sell rating, 16 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.102.102.222.15
Ratings Breakdown: 1 Sell Rating(s)
16 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
16 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
12 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
15 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.4063$9.4063$10.6563$11.8125
Price Target Upside: 54.20% upside64.44% upside68.61% upside70.45% upside

Endo International (NASDAQ:ENDP) Consensus Price Target History

Price Target History for Endo International (NASDAQ:ENDP)

Endo International (NASDAQ:ENDP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2018OppenheimerReiterated RatingHoldLowView Rating Details
5/8/2018Canaccord GenuitySet Price TargetHold$7.00LowView Rating Details
5/8/2018Cantor FitzgeraldSet Price TargetHold$7.00HighView Rating Details
4/4/2018MizuhoDowngradeBuy ➝ Neutral$12.00 ➝ $7.00HighView Rating Details
3/10/2018BarclaysSet Price TargetHold$9.00LowView Rating Details
3/5/2018BMO Capital MarketsLower Price TargetMarket Perform ➝ Market Perform$10.00 ➝ $9.00HighView Rating Details
2/28/2018GabelliDowngradeBuy ➝ HoldHighView Rating Details
2/26/2018JMP SecuritiesDowngradeOutperform ➝ Market PerformLowView Rating Details
2/14/2018B. RileyInitiated CoverageBuy ➝ Buy$10.00HighView Rating Details
1/2/2018Leerink SwannInitiated CoverageOutperform ➝ Outperform$12.00HighView Rating Details
12/12/2017GuggenheimInitiated CoverageNeutral ➝ Neutral$8.50LowView Rating Details
11/10/2017Piper Jaffray CompaniesReiterated RatingHold$7.00N/AView Rating Details
11/10/2017CitigroupLower Price TargetNeutral$9.00 ➝ $7.00N/AView Rating Details
11/10/2017Royal Bank of CanadaLower Price TargetSector Perform ➝ Sector Perform$9.00 ➝ $8.00N/AView Rating Details
9/28/2017Goldman SachsInitiated CoverageSell ➝ Sell$7.00HighView Rating Details
8/10/2017Morgan StanleyLower Price TargetEqual Weight$12.00 ➝ $8.00LowView Rating Details
8/10/2017CowenReiterated RatingHold$16.00HighView Rating Details
8/9/2017Deutsche BankSet Price TargetBuy$15.00 ➝ $13.00LowView Rating Details
6/14/2017William BlairReiterated RatingMarket PerformLowView Rating Details
6/9/2017Stifel NicolausDowngradeBuy ➝ Hold$22.00 ➝ $15.00HighView Rating Details
1/31/2017Susquehanna BancsharesUpgradeNeutral ➝ PositiveN/AView Rating Details
1/20/2017JPMorgan ChaseDowngradeOverweight ➝ Neutral$20.00N/AView Rating Details
9/29/2016Northland SecuritiesUpgradeMarket Perform ➝ Outperform$27.00N/AView Rating Details
8/9/2016UBSReiterated RatingBuy$30.00N/AView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Endo International (NASDAQ:ENDP) Earnings History and Estimates Chart

Earnings by Quarter for Endo International (NASDAQ:ENDP)

Endo International (NASDAQ:ENDP) Earnings Estimates

2018 EPS Consensus Estimate: $2.23
2019 EPS Consensus Estimate: $2.39
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.54$0.59$0.56
Q2 20184$0.49$0.62$0.56
Q3 20184$0.53$0.61$0.56
Q4 20184$0.44$0.63$0.56
Q1 20191$0.58$0.58$0.58
Q2 20191$0.59$0.59$0.59
Q3 20191$0.60$0.60$0.60
Q4 20191$0.62$0.62$0.62

Endo International (NASDAQ ENDP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018$0.54N/AView Earnings Details
5/8/20183/31/2018$0.55$0.67$691.94 million$700.53 millionViewListenView Earnings Details
2/27/2018Before Market$0.62$0.77$762.29 million$768.64 millionViewListenView Earnings Details
11/9/2017Q3$0.85$0.91$794.93 million$786.90 millionViewN/AView Earnings Details
8/8/20176/30/2017$0.74$0.93$832.66 million$875.73 millionViewListenView Earnings Details
5/9/2017Q1 17$1.10$1.23$1.0235 billion$1.0380 billionViewListenView Earnings Details
2/28/2017Q416$1.63$1.77$1.17 billion$1.2420 billionViewListenView Earnings Details
11/8/2016Q316$0.81$1.01$862.47 million$894.30 millionViewListenView Earnings Details
8/8/2016Q216$0.74$0.86$873.50 million$921.00 millionViewListenView Earnings Details
5/5/2016Q116$1.04$1.08$960.96 million$963.54 millionViewListenView Earnings Details
2/29/2016Q415$1.27$1.36$1.07 billion$1.07 billionViewListenView Earnings Details
11/5/2015Q315$1.00$1.02$736.16 million$746.00 millionViewListenView Earnings Details
8/10/2015Q215$1.02$1.08$727.45 million$735.00 millionViewListenView Earnings Details
5/11/2015Q115$1.07$1.17$714.42 million$714.00 millionViewListenView Earnings Details
3/2/2015Q414$1.13$1.16$780.44 million$800.00 millionViewListenView Earnings Details
11/5/2014Q314$0.99$1.15$721.11 million$764.00 millionViewListenView Earnings Details
7/31/2014Q214$0.90$1.06$644.60 million$719.00 millionViewListenView Earnings Details
5/1/2014Q114$0.84$0.92$608.86 million$595.00 millionViewListenView Earnings Details
2/28/2014Q413$0.93$0.96$620.90 million$584.95 millionViewListenView Earnings Details
11/7/2013Q313$1.11$1.34$695.63 million$715.00 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.15$1.42$721.01 million$766.51 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.08$1.09$737.79 million$709.00 millionViewListenView Earnings Details
2/28/2013Q4 2012$1.54$1.62$807.98 million$801.06 millionViewListenView Earnings Details
11/5/2012Q312$1.26$1.28$788.53 million$750.50 millionViewN/AView Earnings Details
8/7/2012$1.19$1.27ViewN/AView Earnings Details
5/1/2012$0.86$0.87ViewN/AView Earnings Details
2/24/2012$1.32$1.40ViewN/AView Earnings Details
10/27/2011$1.28$1.25ViewN/AView Earnings Details
8/9/2011$1.06$1.05ViewN/AView Earnings Details
4/28/2011$1.00$1.00ViewN/AView Earnings Details
2/28/2011$0.97$1.06ViewN/AView Earnings Details
11/1/2010Q3 2010$0.85$0.87ViewN/AView Earnings Details
7/30/2010Q2 2010$0.80$0.81ViewN/AView Earnings Details
4/30/2010Q1 2010$0.75$0.74ViewN/AView Earnings Details
2/22/2010Q4 2009$0.68$0.81ViewN/AView Earnings Details
10/29/2009Q3 2009$0.64$0.63ViewN/AView Earnings Details
7/30/2009Q2 2009$0.67$0.73ViewN/AView Earnings Details
4/29/2009Q1 2009$0.60$0.67ViewN/AView Earnings Details
2/27/2009Q4 2008$0.59$0.66ViewN/AView Earnings Details
10/30/2008Q3 2008$0.52$0.61ViewN/AView Earnings Details
7/31/2008Q2 2008$0.49$0.57ViewN/AView Earnings Details
4/30/2008Q1 2008$0.47$0.51ViewN/AView Earnings Details
2/22/2008Q4 2007$0.44$0.50ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Endo International (NASDAQ:ENDP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Endo International (NASDAQ ENDP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.50%
Institutional Ownership Percentage: 93.06%
Insider Trading History for Endo International (NASDAQ:ENDP)
Institutional Ownership by Quarter for Endo International (NASDAQ:ENDP)

Endo International (NASDAQ ENDP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/15/2017Blaise ColemanCFOBuy6,500$7.89$51,285.0013,729View SEC Filing  
8/15/2017Matthew Joseph MalettaEVPBuy3,000$8.02$24,060.006,984View SEC Filing  
8/14/2017Paul CampanelliCEOBuy6,500$7.71$50,115.00213,620View SEC Filing  
8/10/2017Terrance J CoughlinCOOBuy20,000$7.70$154,000.00181,369View SEC Filing  
3/16/2017Paul CampanelliCEOBuy2,300$10.72$24,656.00207,120View SEC Filing  
3/9/2017Nancy J. HutsonDirectorSell5,325$10.82$57,616.50View SEC Filing  
11/15/2016Roger H. KimmelDirectorSell14,000$17.38$243,320.00View SEC Filing  
5/11/2016Arthur J HigginsDirectorBuy5,000$13.80$69,000.0050,623View SEC Filing  
5/10/2016Arthur J HigginsDirectorBuy11,000$15.42$169,620.0045,623View SEC Filing  
5/10/2016Paul CampanelliInsiderBuy13,000$15.53$201,890.00201,069View SEC Filing  
3/17/2016William SpenglerDirectorBuy1,000$29.20$29,200.0048,835View SEC Filing  
3/16/2016William SpenglerDirectorBuy1,000$35.24$35,240.0047,835View SEC Filing  
3/14/2016Roger H KimmelDirectorBuy1,125$41.94$47,182.5072,237View SEC Filing  
3/7/2016Matthew Joseph MalettaVPBuy500$44.48$22,240.001,000View SEC Filing  
3/7/2016Silva Rajiv DeCEOBuy2,250$44.50$100,125.00250,705View SEC Filing  
3/1/2016Nancy J. HutsonDirectorSell3,413$42.19$143,994.4739,990View SEC Filing  
11/12/2015Shane CookeDirectorBuy4,000$57.13$228,520.0010,179View SEC Filing  
11/11/2015Michael HyattDirectorSell8,000$55.48$443,840.00251,599View SEC Filing  
11/11/2015Paul CampanelliinsiderBuy2,100$55.69$116,949.0015,367View SEC Filing  
11/11/2015Silva Rajiv DeCEOBuy9,006$55.52$500,013.1213,697View SEC Filing  
11/11/2015Suketu UpadhyayCFOBuy4,450$56.37$250,846.5017,740View SEC Filing  
11/11/2015Susan HallEVPBuy1,000$55.35$55,350.007,515View SEC Filing  
6/16/2015Arthur J HigginsDirectorBuy2,500$81.10$202,750.00View SEC Filing  
4/8/2015Caroline B ManogueVPSell105,562$91.90$9,701,147.80View SEC Filing  
11/14/2014Suketu UpadhyayCFOBuy3,700$66.94$247,678.00View SEC Filing  
8/5/2014Arthur J HigginsDirectorBuy3,500$65.65$229,775.00View SEC Filing  
6/9/2014John DeluccaDirectorSell6,764$68.83$465,566.12View SEC Filing  
5/29/2014Caroline B ManogueVPSell175,033$72.02$12,605,876.66View SEC Filing  
5/1/2014John DeluccaDirectorSell8,094$66.31$536,713.1421,596View SEC Filing  
4/1/2014John DeluccaDirectorSell10,384$68.46$710,888.6421,596View SEC Filing  
3/10/2014Arthur HigginsDirectorBuy5,000$73.00$365,000.005,000View SEC Filing  
3/10/2014Ivan GergelEVPSell75,637$72.47$5,481,413.3927,649View SEC Filing  
8/26/2013Caroline ManogueVPSell145,592$39.40$5,736,324.8046,422View SEC Filing  
8/8/2013Roger KimmelDirectorBuy5,478$36.50$199,947.0051,914View SEC Filing  
4/9/2013Caroline B ManogueVPSell35,000$35.00$1,225,000.00View SEC Filing  
11/12/2012David HolveckCEOBuy7,425$26.84$199,287.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Endo International (NASDAQ ENDP) News Headlines

Source:
DateHeadline
Endo International plc (ENDP) Expected to Announce Quarterly Sales of $680.67 MillionEndo International plc (ENDP) Expected to Announce Quarterly Sales of $680.67 Million
www.americanbankingnews.com - May 20 at 1:54 AM
 Brokerages Anticipate Endo International plc (ENDP) Will Announce Earnings of $0.55 Per Share Brokerages Anticipate Endo International plc (ENDP) Will Announce Earnings of $0.55 Per Share
www.americanbankingnews.com - May 18 at 11:23 PM
Broadfin pumps $50M into Raleighs BDSIBroadfin pumps $50M into Raleigh's BDSI
www.bizjournals.com - May 17 at 7:02 PM
BidaskClub Upgrades Endo International (ENDP) to "Sell"BidaskClub Upgrades Endo International (ENDP) to "Sell"
www.americanbankingnews.com - May 16 at 11:04 AM
Endo International plc Expected to Post Q2 2018 Earnings of $0.60 Per Share (ENDP)Endo International plc Expected to Post Q2 2018 Earnings of $0.60 Per Share (ENDP)
www.americanbankingnews.com - May 16 at 7:16 AM
US state attorneys general sue Purdue Pharma over opioid epidemicUS state attorneys general sue Purdue Pharma over opioid epidemic
www.cnbc.com - May 15 at 5:53 PM
BRIEF-Paulson & Co Ups Share Stake In Discovery, Endo InternationalBRIEF-Paulson & Co Ups Share Stake In Discovery, Endo International
www.reuters.com - May 15 at 5:53 PM
Endo International (ENDP) Rating Reiterated by OppenheimerEndo International (ENDP) Rating Reiterated by Oppenheimer
www.americanbankingnews.com - May 14 at 12:42 PM
Endo International plc (ENDP) Short Interest Down 4.7% in AprilEndo International plc (ENDP) Short Interest Down 4.7% in April
www.americanbankingnews.com - May 13 at 1:40 AM
FY2022 Earnings Forecast for Endo International plc Issued By Gabelli (ENDP)FY2022 Earnings Forecast for Endo International plc Issued By Gabelli (ENDP)
www.americanbankingnews.com - May 11 at 11:53 AM
FY2020 EPS Estimates for Endo International plc Boosted by Analyst (ENDP)FY2020 EPS Estimates for Endo International plc Boosted by Analyst (ENDP)
www.americanbankingnews.com - May 11 at 11:47 AM
Endo International plc (ENDP) Given Average Rating of "Hold" by AnalystsEndo International plc (ENDP) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 10 at 4:59 PM
FY2020 EPS Estimates for Endo International plc (ENDP) Decreased by Piper JaffrayFY2020 EPS Estimates for Endo International plc (ENDP) Decreased by Piper Jaffray
www.americanbankingnews.com - May 10 at 9:07 AM
Endo International plc (ENDP) to Post Q2 2018 Earnings of $0.51 Per Share, Leerink Swann ForecastsEndo International plc (ENDP) to Post Q2 2018 Earnings of $0.51 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - May 10 at 6:54 AM
Q2 2018 Earnings Forecast for Endo International plc (ENDP) Issued By Piper JaffrayQ2 2018 Earnings Forecast for Endo International plc (ENDP) Issued By Piper Jaffray
www.americanbankingnews.com - May 9 at 8:48 AM
Edited Transcript of ENDP earnings conference call or presentation 8-May-18 11:30am GMTEdited Transcript of ENDP earnings conference call or presentation 8-May-18 11:30am GMT
finance.yahoo.com - May 9 at 8:11 AM
Wired News - Lannett Announced Acquisition of 23 Approved Drug Product Applications from Endo Internationals SubsidiaryWired News - Lannett Announced Acquisition of 23 Approved Drug Product Applications from Endo International's Subsidiary
finance.yahoo.com - May 9 at 8:11 AM
Endo International (ENDP) Given a $7.00 Price Target at Canaccord GenuityEndo International (ENDP) Given a $7.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - May 8 at 6:26 PM
Endo up 5% on Q1 results; reiterates guidanceEndo up 5% on Q1 results; reiterates guidance
seekingalpha.com - May 8 at 5:47 PM
Endo International (ENDP) Given a $7.00 Price Target by Cantor Fitzgerald AnalystsEndo International (ENDP) Given a $7.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - May 8 at 3:28 PM
Endo International (ENDP) Releases Quarterly  Earnings ResultsEndo International (ENDP) Releases Quarterly Earnings Results
www.americanbankingnews.com - May 8 at 12:13 PM
Endo International (ENDP) Issues FY18 Earnings GuidanceEndo International (ENDP) Issues FY18 Earnings Guidance
www.americanbankingnews.com - May 8 at 9:36 AM
ENDO INTERNATIONAL PLCENDO INTERNATIONAL PLC
www.streetinsider.com - May 8 at 8:09 AM
BRIEF-Endo Posts Q1 Adj. Earnings $0.67/Shr From Continuing OperationsBRIEF-Endo Posts Q1 Adj. Earnings $0.67/Shr From Continuing Operations
www.reuters.com - May 8 at 8:09 AM
Earnings Reaction History: Endo International plc, 54.5% Follow-Through Indicator, 12.9% SensitiveEarnings Reaction History: Endo International plc, 54.5% Follow-Through Indicator, 12.9% Sensitive
www.nasdaq.com - May 8 at 8:09 AM
Endo International (ENDP) Tops Q1 EPS by 12c, Affirms GudianceEndo International (ENDP) Tops Q1 EPS by 12c, Affirms Gudiance
www.streetinsider.com - May 8 at 8:09 AM
Endo Reports First-Quarter 2018 Financial ResultsEndo Reports First-Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 8:09 AM
Endo shares rise 5% after Q1 profit, revenue beatsEndo shares rise 5% after Q1 profit, revenue beats
finance.yahoo.com - May 8 at 8:09 AM
Endo beats as Xiaflex sales, injectables business growEndo beats as Xiaflex sales, injectables business grow
finance.yahoo.com - May 8 at 8:09 AM
Drugmaker Endo posts wider quarterly lossDrugmaker Endo posts wider quarterly loss
finance.yahoo.com - May 8 at 8:09 AM
Endo International (ENDP) Rating Lowered to Strong Sell at ValuEngineEndo International (ENDP) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - May 3 at 10:55 PM
$687.14 Million in Sales Expected for Endo International plc (ENDP) This Quarter$687.14 Million in Sales Expected for Endo International plc (ENDP) This Quarter
www.americanbankingnews.com - May 3 at 4:01 AM
UPDATE 2-Indiviors Q1 profit slips, shares fall on top drug let-downUPDATE 2-Indivior's Q1 profit slips, shares fall on top drug let-down
www.reuters.com - May 2 at 8:15 AM
Endo International (ENDP) Rating Increased to Hold at Zacks Investment ResearchEndo International (ENDP) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - May 1 at 12:26 PM
Zacks: Analysts Expect Endo International plc (ENDP) Will Post Earnings of $0.54 Per ShareZacks: Analysts Expect Endo International plc (ENDP) Will Post Earnings of $0.54 Per Share
www.americanbankingnews.com - May 1 at 9:18 AM
Endo International (ENDP) Scheduled to Post Earnings on TuesdayEndo International (ENDP) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - May 1 at 5:50 AM
Endo Pharmaceuticals Earnings PreviewEndo Pharmaceuticals Earnings Preview
seekingalpha.com - April 30 at 8:15 AM
Blog Exposure - Endo International to Acquire Somerset Therapeutics and its Affiliate Wintac LtdBlog Exposure - Endo International to Acquire Somerset Therapeutics and its Affiliate Wintac Ltd
finance.yahoo.com - April 30 at 8:15 AM
Collagenase Clostridium Histolyticum For The Investigational Treatment Of Cellulite To Be Featured During The Hot ...Collagenase Clostridium Histolyticum For The Investigational Treatment Of Cellulite To Be Featured During The Hot ...
www.prnewswire.com - April 28 at 8:21 AM
Endo International (ENDP) to Acquire Somerset Therapeutics for $190MEndo International (ENDP) to Acquire Somerset Therapeutics for $190M
www.streetinsider.com - April 28 at 8:21 AM
Collagenase Clostridium Histolyticum For The Investigational Treatment Of Cellulite To Be Featured During The Hot Topics Symposium At The Aesthetic Meeting 2018Collagenase Clostridium Histolyticum For The Investigational Treatment Of Cellulite To Be Featured During The Hot Topics Symposium At The Aesthetic Meeting 2018
finance.yahoo.com - April 27 at 8:24 AM
Endo International plc (ENDP) Sees Large Decline in Short InterestEndo International plc (ENDP) Sees Large Decline in Short Interest
www.americanbankingnews.com - April 27 at 2:58 AM
Endo International to acquire Somerset Therapeutics for $190MEndo International to acquire Somerset Therapeutics for $190M
seekingalpha.com - April 26 at 5:21 PM
Endo to Acquire Somerset Therapeutics and Business of Affiliate Wintac LimitedEndo to Acquire Somerset Therapeutics and Business of Affiliate Wintac Limited
finance.yahoo.com - April 26 at 5:21 PM
$190M deal: Endo buying North Jersey specialty pharma company$190M deal: Endo buying North Jersey specialty pharma company
finance.yahoo.com - April 26 at 5:21 PM
ENDO Arm Gets Health Canada Nod for TreatmentENDO Arm Gets Health Canada Nod for Treatment
www.baystreet.ca - April 23 at 5:18 PM
Paladin Labs Inc. Announces Launch of New Indication for XIAFLEX® (Collagenase Clostridium Histolyticum), Broadening Its Use to the Treatment of Appropriate Patients with Peyronies DiseasePaladin Labs Inc. Announces Launch of New Indication for XIAFLEX® (Collagenase Clostridium Histolyticum), Broadening Its Use to the Treatment of Appropriate Patients with Peyronie's Disease
finance.yahoo.com - April 23 at 8:10 AM
Paladin Labs Announces the Launch of Unisom® Snore Relief, the Only Natural Health Product Throat Spray Available in Canada to Help Relieve Symptoms Associated with SnoringPaladin Labs Announces the Launch of Unisom® Snore Relief, the Only Natural Health Product Throat Spray Available in Canada to Help Relieve Symptoms Associated with Snoring
finance.yahoo.com - April 19 at 8:09 AM
Are Earnings Prospects Improving For Loss-Making Endo International plc’s (NASDAQ:ENDP)?Are Earnings Prospects Improving For Loss-Making Endo International plc’s (NASDAQ:ENDP)?
finance.yahoo.com - April 18 at 5:50 PM
Leerink Swann Analysts Increase Earnings Estimates for Endo International plc (ENDP)Leerink Swann Analysts Increase Earnings Estimates for Endo International plc (ENDP)
www.americanbankingnews.com - April 18 at 8:39 AM

SEC Filings

Endo International (NASDAQ:ENDP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Endo International (NASDAQ:ENDP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Endo International (NASDAQ ENDP) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.